Wang, T. Tiffany
Yang, Jun
Zhang, Yong
Zhang, Meili
Dubois, Sigrid
Conlon, Kevin C.
Tagaya, Yutaka
Hamele, Cait E.
Dighe, Shubha
Olson, Thomas L.
Feith, David J.
Azimi, Nazli
Waldmann, Thomas A.
Loughran, Thomas P. Jr.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA044579, P30CA044579, R01CA178393, R01CA098472, P30CA044579, R01CA178393, R01CA098472, P30CA044579, R01CA178393, R01CA098472, P30CA044579, R01CA178393, R01CA098472, P30CA044579, R01CA178393, R01CA098472, P30CA044579, R01CA178393, R01CA098472)
U.S. Department of Health & Human Services | National Institutes of Health (R01CA098472, R01CA178393)
Article History
Received: 29 March 2018
Revised: 13 July 2018
Accepted: 7 August 2018
First Online: 23 October 2018
Compliance with ethical standards
:
: Nazli Azimi and Yutaka Tagaya are employed by BIONIZ Therapeutics, the producer of BNZ-1. Thomas Loughran, Jr. and Thomas Waldmann are on the scientific advisory board of BIONIZ Therapeutics. The remaining authors declare that they have no conflict of interest.